You are here:

rivastigmine (Exelon)

Advice

In the absence of a submission from the holder of the marketing authorisation.

Rivastigmine (Exelon) is not recommended for use within NHS Scotland for the treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Drug Details

Drug Name: rivastigmine (Exelon)
SMC Drug ID: 310/06
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Mild to moderately severe dementia in patients with idiopathic Parkinson’s disease
BNF Category:
Sub Category: 4.11 Drugs for dementia
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 7 August 2006

Back